QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-half 2024 performance and its continued ...

"This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to ...

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) reported Q4 CY2025 results , with sales up 2.2% year on year to $723 ...

QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago. These figures ...

SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) ...

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care ...

QuidelOrtho's revenue is shifting, with Labs growing 74% YoY, offsetting a 54% decline in Point of Care post-COVID. The company has stable recurring revenues, primarily from North America, but faces ...

Detailed price information for Quidelortho Corp (QDEL-Q) from The Globe and Mail including charting and trades.

QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter 2024 results, is expected to ...